Tidal Investments LLC Boosts Stock Position in The Cooper Companies, Inc. $COO

Key Points

• Tidal Investments increased its Cooper Companies position by 281.4% in the second quarter, adding 61,165 shares to hold 82,903 shares valued at approximately $5.95 million.
• Cooper’s adjusted fiscal Q3 earnings beat expectations at $1.15 per share, but revenue of about $1.07 billion fell short of forecasts amid U.S. channel destocking and weakness in CooperVision.
• Management lowered fiscal 2026 earnings guidance to $4.51–$4.55 per share, prompting analyst downgrades and price-target cuts. The company nevertheless authorized a $3 billion share-repurchase program, including an additional $1 billion authorization.

Tidal Investments LLC increased its holdings in The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 281.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 82,903 shares of the medical device company's stock after purchasing an additional 61,165 shares during the period. Tidal Investments LLC's holdings in Cooper Companies were worth $5,945,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Root Financial Partners LLC lifted its position in Cooper Companies by 104.5% during the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company's stock valued at $26,000 after purchasing an additional 162 shares during the last quarter. Avalon Trust Co bought a new stake in shares of Cooper Companies in the 2nd quarter worth about $25,000. SJS Investment Consulting Inc. increased its holdings in shares of Cooper Companies by 107.5% in the 1st quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company's stock worth $26,000 after buying an additional 187 shares during the last quarter. Elevation Wealth Partners LLC raised its position in shares of Cooper Companies by 1,136.4% during the 2nd quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company's stock valued at $29,000 after buying an additional 375 shares in the last quarter. Finally, Continuum Advisory LLC purchased a new stake in shares of Cooper Companies during the 2nd quarter valued at about $30,000. Hedge funds and other institutional investors own 24.39% of the company's stock.

More Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper reported adjusted fiscal Q3 earnings of $1.15 per share, ahead of the approximately $1.11–$1.12 consensus, with earnings up from $0.49 a year earlier. Cost controls and continued fertility-related growth helped offset weakness elsewhere. Cooper Companies Bets on Fertility Growth Despite Weakness in CooperVision
• Positive Sentiment: The board authorized an additional $1 billion of repurchases, bringing the total buyback authorization to $3 billion. The program could support per-share earnings and signal management believes COO shares are undervalued. Cooper Outlines Q4 EPS and Adds to Buyback Authorization
• Neutral Sentiment: Cooper completed a strategic review but chose not to pursue a sale or separate transaction for CooperSurgical. Keeping the business preserves its fertility-growth opportunity, but investors had apparently anticipated a potential deal or value-unlocking action. Cooper Cos. Stock Drops After Soft Outlook and No Deal
• Negative Sentiment: Revenue rose only about 1% to $1.066 billion, missing the roughly $1.10 billion consensus. U.S. channel destocking and inventory reductions pressured CooperVision, raising concerns about near-term demand and sales momentum. COO Q3 Earnings Top Estimates, Revenues Miss on Destocking
• Negative Sentiment: Management reduced fiscal 2026 earnings guidance to $4.51–$4.55 per share and issued fourth-quarter guidance of $1.05–$1.09, below prior expectations. The weaker outlook triggered multiple analyst downgrades and price-target cuts, including from Baird, UBS, JPMorgan and William Blair.
• Negative Sentiment: Law firms have announced securities-fraud investigations connected with the post-earnings decline. These notices are often promotional, but they add to negative investor sentiment and potential legal uncertainty. Securities Fraud Investigation Into Cooper Companies Announced

Cooper Companies Price Performance

NASDAQ:COO opened at $53.91 on Monday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.22 and a quick ratio of 0.73. The Cooper Companies, Inc. has a 1-year low of $51.01 and a 1-year high of $89.83. The company has a 50-day moving average of $71.62 and a 200 day moving average of $69.61. The firm has a market cap of $10.25 billion, a PE ratio of 18.40, a price-to-earnings-growth ratio of 2.19 and a beta of 0.82.

Cooper Companies (NASDAQ:COO - Get Free Report) last posted its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.12 by $0.03. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The business had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same quarter in the previous year, the business posted $0.49 EPS. The company's quarterly revenue was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, research analysts anticipate that The Cooper Companies, Inc. will post 4.53 EPS for the current fiscal year.

Cooper Companies announced that its board has authorized a share repurchase program on Wednesday, September 9th that authorizes the company to buyback $3.00 billion in shares. This buyback authorization authorizes the medical device company to reacquire up to 22.7% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's leadership believes its shares are undervalued.

Wall Street Analyst Weigh In

Several research analysts recently commented on COO shares. Citigroup reiterated a "neutral" rating and issued a $60.00 price target (down from $80.00) on shares of Cooper Companies in a research report on Thursday. JPMorgan Chase & Co. lowered their price objective on Cooper Companies from $71.00 to $58.00 and set a "neutral" rating for the company in a research note on Thursday. BNP Paribas Exane dropped their price objective on shares of Cooper Companies from $95.00 to $92.00 and set an "outperform" rating for the company in a research note on Monday, June 8th. Wells Fargo & Company set a $61.00 target price on Cooper Companies and gave the company an "equal weight" rating in a research note on Thursday. Finally, Piper Sandler cut shares of Cooper Companies from an "overweight" rating to a "neutral" rating and cut their price target for the stock from $86.00 to $59.00 in a report on Thursday. Five research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $71.47.

Cooper Companies Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.